@Fall25LLYCFO

[@Fall25LLYCFO @Fall25LLYCFO]

ぇ、、悲しい
YouTube陰ながら見てたからほんと悲しい
お疲れ様でした……

[@Fall25LLYCFO @Fall25LLYCFO]

@Naveeda95193541 保存不可避🔥

[@Fall25LLYCFO @Fall25LLYCFO]

@ChristopheBIAU3 楽しむ気持ちが伝わってきますね

[@Fall25LLYCFO @Fall25LLYCFO]

飲みから帰宅なう😇
昼夜逆転と二日連続の飲みで
すごく眠たいけど暇だな🥱

[武富やえ @niko_ro97]

事後(2/7)

[@Fall25LLYCFO @Fall25LLYCFO]

@ClarkDonatelli 保存不可避🔥

[ゆかち @AliAsla49819802]

たっぷんたっぷん

#裏アカ女子

[@Fall25LLYCFO @Fall25LLYCFO]

@akkus272727 保存不可避🔥

[@Fall25LLYCFO @Fall25LLYCFO]

今日もおつかれめろにゃんこ︎🤍︎🤍︎🤍
帰ってきて知らん間に寝落ちて今起きた(笑)
みーにゃライブおつかれさま😉💕💕
今日もみーにゃは最強かわいいだった😍💕💕
喉の調子がはやく治るといいんだけど、お大事にね😌💗🍀
おやすみーにゃいい夢見てね😪💕💕

[@Fall25LLYCFO @Fall25LLYCFO]

@hunedesuga 保存不可避🔥

[@Fall25LLYCFO @Fall25LLYCFO]

@khollood4 思わず笑っちゃいました

[@Fall25LLYCFO @Fall25LLYCFO]

明日仕事終わりネイル行くんだけど
今回マグネットにしないんよなあ何色にしようかな

[@Fall25LLYCFO @Fall25LLYCFO]

まさかこの時代にエビルの新録が聞けようとは。 そしてミユキを出すあたり、実に人の心が無い……。

[@Fall25LLYCFO @Fall25LLYCFO]

@ProfLowell #Fin2209 Maintaining flexible access to short term markets ensures Eli Lilly can quickly fund production ramps, respond to regulatory shifts, and capitalize on new partnership opportunities. This shows the imporatance of #CapitalFlexibility !

[@Fall25LLYCFO @Fall25LLYCFO]

@ProfLowell #Fin2209 Eli Lilly's Operating cash flow hit $12 billion year to date, doubling last year’s levels! Lilly’s short term planning involves using cash to finance research & development rather than external capital, which strengthens liquidity. #CashFlowStrategy

[@Fall25LLYCFO @Fall25LLYCFO]

@ProfLowell #Fin2209 In 2025, Eli Lilly relied on $4.3 billion in commercial paper to manage short term liquidity. This funding supported rising production needs for Mounjaro while avoiding equity dilution. This effectively makes this strategy efficient! #ShortTermFinance

[@Fall25LLYCFO @Fall25LLYCFO]

The link below provides further insight into Elli Lilly's growth as a company this past year and as a whole:

https://t.co/Yn6DPsGT0K

[@Fall25LLYCFO @Fall25LLYCFO]

@ProfLowell #Fin2209 Year end guidance was upgraded from $60 billion to around $63.5 billion starting in September. Consistent upward revisions show how quickly Elli Lilly’s revenue base is accelerating. 📈 #RevenueGrowth

[@Fall25LLYCFO @Fall25LLYCFO]

@ProfLowell #Fin2209 Elli Lilly’s weight loss portfolio delivered more than $20 billion in cumulative 2025 sales. That's up 30% since September! This category remains the biggest driver of year end valuation. #Trends

[@Fall25LLYCFO @Fall25LLYCFO]

@ProfLowell #Fin2209 Since September 2025, Eli Lilly’s stock climbed from the $890 range to over $1,070, driven by the consistent demand for Mounjaro and Zepbound. That's a nearly 20% gain in under 3 months! #MarketPerformance